[{"orgOrder":0,"company":"Mediforum","sponsor":"Vision Sensing Acquisition Corp","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2024","type":"Merger","leadProduct":"PM012","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Mediforum","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Mediforum \/ Vision Sensing Acquisition Corp","highestDevelopmentStatusID":"9","companyTruncated":"Mediforum \/ Vision Sensing Acquisition Corp"}]

Find Clinical Drug Pipeline Developments & Deals by Mediforum

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          ACS GCI
                          Not Confirmed
                          ACS GCI
                          Not Confirmed

                          Details : The combined company will advance Mediforum's drugs, PM012 for Alzheimer’s Disease and MF018 for chemotherapy-induced peripheral neuropathy, currently in Phase 2b trials.

                          Product Name : PM012

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          January 16, 2024

                          Lead Product(s) : PM012

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase II/ Phase III

                          Sponsor : Vision Sensing Acquisition Corp

                          Deal Size : Undisclosed

                          Deal Type : Merger

                          blank